FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ngton, D.C. 20549	
•	OI

ı	OMB APP	OMB APPROVAL								
	OMB Number:	3235-0287								
l	Estimated average bu	ırden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     EVNIN LUKE					2. Issuer Name and Ticker or Trading Symbol EnteroMedics Inc [ ETRM ]							ationship of k all applica Director	ble)	Person X	10% Ow	ner
		rst) IANAGEMENT ST., 54TH FLOO			3. Date of Earliest Transaction (Month/Day/Year) 09/30/2010						Officer (g below)	give title		Other (sp	specify	
(Street) BOSTON (City)	M.	A	02116 (Zip)	4.	. If Ame	endment, Da	te of	Original Filed	(Month/Day	Year)	Line)	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Ta	able I - Non-D	) Derivati	ive S	ecurities	Acc	uired, Dis	posed of	, or Ben	eficially	Owned				
1. Title of Security (Instr. 3)							3. Transaction Code (Instr	Disposed	es Acquired Of (D) (Insti	d (A) or r. 3, 4 and 5)	or 5. Amoun Securities Beneficial Owned Fo		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct Indirect Etr. 4)	7. Nature of Indirect Beneficial Ownership	
				Code V			Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 an				(Instr. 4)		
			Table II - De					ired, Disp options, o				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transa Code (		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Common Stock Warrant (Right to Buy)	\$2.15	09/30/2010		P		704,607 <sup>(1)</sup>		(2)(4)	(2)	Common Stock	704,607	\$0.125	704,60	07	I	See footnote <sup>(1)</sup>
Series A Non-Voting Convertible Preferred	(3)	09/30/2010		P		704,607 <sup>(5)</sup>		(3)(4)	(3)	Common Stock	704,607	\$1.72	704,60	07	I	See footnote <sup>(5)</sup>

## **Explanation of Responses:**

- 1. The Warrants were purchased and are held as follows: 586,338 by MPM BioVentures III QP, L.P. ("BV III QP"), 39,423 by MPM BioVentures III, L.P. ("BV III"), 11,584 by MPM Asset Management Investors 2002 BVIII LLC ("AM 2002"), 17,714 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 49,548 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"). MPM BioVentures III GP, L.P. ("MPM BioVentures III GP, L.P. ("BV III QP"), 20,423 by MPM BioVentures III GP, L.P. ("BV III"), 11,584 by MPM BioVentures III GP, L.P. ("BV III"), 12,584 by MPM BioVenture III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III, BV Parallel and BV KG. The Reporting Person is a Series A member of MPM III LLC and a manager of AM 2002. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- 2. The Warrant exercise period (the "Exercise Period") shall begin on the later to occur of (a) the date that is 181 days from the date of the issuance of the Warrant and (b) the date on which the Equity Offering (as defined in Securites Purchase Agreement dated September 30, 2010 by and between the Issuer and the Purchasers) commences, and shall end on the fifth anniversary of the date on which the Exercise Period begins.
- 3. The Series A Non-Voting Convertible Preferred Stock is convertible into Common Stock at any time on a one-for-one basis, and has no expiration date
- 4. No Reporting Person shall be permitted to convert an amount of Convertible Preferred Stock or exercise the Warrants for an amount of Common Stock that would result in such holder owning more than 19.99% of the Issuer's Common Stock oustanding after such conversion and/or exercise.
- 5. The shares were purchased and are held as follows: 586,338 by BV III QP, 39,423 by BV III, 11,584 by AM 2002, 17,714 by BV Parallel and 49,548 by BV KG. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein

10/04/2010 /s/ Luke Evnin

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.